Metastatic Solid Tumors

Also known as: Metastatic Solid Tumor

DrugDrug NameDrug Description
DB14723LarotrectinibLarotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Originally discovered by Array BioPharma, the agent was ultimately licensed to Loxo Oncology in 2013. Larotrectinib is another example of innovative new cancer therapy medications that target key, specific genetic biomarker drivers of cancer rather than particular types of tumors [L4847].
DB09037PembrolizumabPembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation.[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.[F136] It was developed by Merck & Co and firstly approved for the treatment of metastatic malignant melanoma. This is the first approved therapy against PD-1.[A7624] It was approved firstly by the FDA on September 4, 2014.[L2954] Its approval in melanoma was extended to several countries such as Australia, Israel, Korea, Macau, the European Union and the United Arab Emirates.[A33350] On June 12, 2018, Pembrolizumab was approved for the treatment of cervical cancer under the status of accelerated approval.[L2955]
DrugDrug NamePhaseStatusCount
DB12565Abexinostat1Active Not Recruiting1
DB06013Aldoxorubicin1Completed1
DB12015Alpelisib1Completed1
DB11945Avelumab1Recruiting1
DB15399BMS-7548071Completed1
DB15286CB-11581Not Yet Recruiting1
DB00958Carboplatin1Completed2
DB05239Cobimetinib1Recruiting1
DB01248Docetaxel1Recruiting1
DB11986Entrectinib1Active Not Recruiting1
DB00530Erlotinib1Completed1
DB14951Etirinotecan pegol1Completed1
DB00441Gemcitabine1Active Not Recruiting1
DB00441Gemcitabine1Completed1
DB11886Infigratinib1Completed1
DB06186Ipilimumab1Recruiting1
DB11740MK-17751Completed1
DB09035Nivolumab1Recruiting1
DB06306Onalespib1Completed1
DB12638PU-H711Active Not Recruiting1
DB01229Paclitaxel1Active Not Recruiting1
DB01229Paclitaxel1Completed1
DB06589Pazopanib1Active Not Recruiting1
DB14904Pimasertib1Completed1
DB01132Pioglitazone1Completed1
DB01030Topotecan1Completed1
DB12400Voxtalisib1Completed1
DB12498Mogamulizumab1 / 2Recruiting1
DB00619Imatinib2Withdrawn1